In multiple logistic regression analysis among patients who received NVP or EFV, we found a higher baseline CD4 cell counts (per 100-cell/μl increase, adjusted odds ratio [AOR], 1.125; 95% confidence interval [95% CI], 1.031–1.228) and use of NVP plus 2 NRTIs (AOR, 2.443; 95% CI, 1.816–3.286) were independently associated with the development of skin rashes (Table 3). This evidence concerns the gene CD4 and exanthem.